Evidence map›Paper›PMID 31190781›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2019

Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study.

Victoria Federico Paly, Ian Naya, Necdet B Gunsoy, Maurice T Driessen, Nancy Risebrough, Andrew Briggs, Afisi S Ismaila

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Victoria Federico PalyICON Health Economics, ICON, Philadelphia, PA, USA.ORCID 0000-0003-3508-1296
Ian NayaGlobal Respiratory Franchise, GSK, Brentford, Middlesex, UK.ORCID 0000-0002-2263-1407
Necdet B GunsoyValue Evidence and Outcomes, GSK, Uxbridge, Middlesex, UK.ORCID 0000-0003-1298-2462
Maurice T DriessenValue Evidence & Outcomes, GSK, Brentford, Middlesex, UK.
Nancy RisebroughICON Health Economics, ICON, Toronto, ON, Canada.ORCID 0000-0001-6572-3021
Andrew BriggsHealth Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Afisi S IsmailaValue Evidence & Outcomes, GSK, Collegeville, PA, USA.ORCID 0000-0002-2876-8308
GlaxoSmithKline (United States) · USHealth Economics and Outcomes Research (United Kingdom) · GBMiddlesex University · GBUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Health Care CostsAgedBronchodilator AgentsCost-Benefit AnalysisCost SavingsDisease ProgressionDouble-Blind MethodFemaleFluticasone-Salmeterol Drug CombinationForced Expiratory VolumeGlucocorticoidsHumansLungMaleMiddle AgedProspective StudiesBronchodilator AgentsFluticasone-Salmeterol Drug CombinationGlucocorticoidsdirect medical costsEQ-5Dresource utilizationutilities

Identifiers

PMID31190781
PMCPMC6524132
OpenAlexW2943572989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.